Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8PP0

Crystal structure of Retinoic Acid Receptor alpha (RXRA) in complexed with JP147

Summary for 8PP0
Entry DOI10.2210/pdb8pp0/pdb
DescriptorRetinoic acid receptor RXR-alpha, Nuclear receptor coactivator 2, 3-[4-[2,3-dihydro-1H-inden-4-yl(methyl)amino]-6-(trifluoromethyl)pyrimidin-2-yl]oxypropanoic acid, ... (4 entities in total)
Functional Keywordsrxr alpha, inhibitor, structural genomics, structural genomics consortium, sgc, dna binding protein
Biological sourceHomo sapiens (human)
More
Total number of polymer chains2
Total formula weight29198.70
Authors
Chaikuad, A.,Pollinger, J.,Merk, D.,Knapp, S.,Structural Genomics Consortium (SGC) (deposition date: 2023-07-05, release date: 2024-02-07, Last modification date: 2024-02-21)
Primary citationLewandowski, M.,Carmina, M.,Knumann, L.,Sai, M.,Willems, S.,Kasch, T.,Pollinger, J.,Knapp, S.,Marschner, J.A.,Chaikuad, A.,Merk, D.
Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical Properties.
J.Med.Chem., 67:2152-2164, 2024
Cited by
PubMed Abstract: Retinoid X receptors (RXRs, NR2B1-3) hold therapeutic potential in oncology, neurodegeneration, and metabolic diseases, but traditional RXR agonists mimicking the natural ligand 9- retinoic acid exhibit poor physicochemical properties, pharmacokinetics, and safety profiles. Improved RXR ligands are needed to exploit RXR modulation as a promising therapeutic concept in various indications beyond its current role in second-line cancer treatment. Here, we report the co-crystal structure of RXR in complex with a novel pyrimidine-based ligand and the structure-informed optimization of this scaffold to highly potent and highly soluble RXR agonists. Focused structure-activity relationship elucidation and rigidization resulted in a substantially optimized partial RXR agonist with low nanomolar potency, no cytotoxic activity, and very favorable physicochemical properties highlighting this promising scaffold for the development of next-generation RXR targeting drugs.
PubMed: 38237049
DOI: 10.1021/acs.jmedchem.3c02095
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.9 Å)
Structure validation

227561

數據於2024-11-20公開中

PDB statisticsPDBj update infoContact PDBjnumon